 NEWTON, Mass., Aug. 2, 2021 PRNewswire -- Karyopharm Therapeutics Inc. Nasdaq: KPTI, a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Compensation Committee of Karyopharms Board of Directors granted stock options to purchase an aggregate of 74,600 shares of Karyopharms common stock to 11 newly-hired employees, with a grant date of July 30, 2021. 